All my posts are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on. For a complete disclaimerclick here
All my posts are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on. For a complete disclaimerclick here
Highlights / Synopsis from the ENTB CEO update today:
- they are very excited about bringing Dr. Bogin on the team
- Dr. Bogin will put them in a position to identify key protocols
- will help speed up FDA approval
- the identification of new stem cell line gives them a dramatic and envious platform from which to move forward from
- other scientists working with stem cells may find their platform advantageous or useful to their own line of study which will create added revenue from research companies and pharmaceuticals
- very excited about their cancer immunotherapy vaccine which they are initially rolling out to the vetrinary market. Represents a significant near term revenue stream
- COPD is the fourth leading cause of death in the United States
- no one has come up with a cure to cause lung capacity to regenerate and this is what they are focused on doing
- they feel very confident about FDA approval. Their vaccine which activates stem cells in the body couple with the laser technology which paints the tissue and attracts stem cells to it should get them to the market place faster than other directions they could have gone in
Shareholders were then allowed to ask questions. This will be the first of a townhall like broadcast.
Key Points:
Share structure: Only 2.7 million shares available in the public float. They are not interested in flooding the market with stock and want to keep the tight share structure. Their goal is to focus on research and execution
Moving to a Higher Exchange: The higher up they go in price the more visibility and credibility they get and they are interested in applying to a higher exchange
They are fully reporting on the OTC and not interested in doing any kind of forward split or reverse split. They love their share structure just the way that it is
They are being watched right now by larger stem cell companies but the highest priority now is setting up the protocols
Dr. Bogin is currently analyzing current clinical trials to determine the best direction to proceed in. His clinical background helps with their roadmand and everyone is excited about the journey. His involvement is having an immediate impact
They are not concerned about their cash burn rate because they expect revenue in the next 9 - 12 months from their canine cancer immunotherapy. This will also provide great clinical data for later human trials.
They are estimating grossing $62 million dollars from their first year of canine cancer immunotherapy
All my posts are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on. For a complete disclaimerclick here
-Ultimate goal of the company is getting stem cell and photoceutical device treatment for COPD approved by FDA.
-Recent achievement: Cell line that they have identified in their labrotory research. This gives them a great platform for moving forward with their stem cell cure for COPD. It also puts them in a position to sell this stem cell line to other researches/pharamaceutical companies...CEO believes this is a very near term revenue source for them.
-Cancer immuno-therapy vaccine. Rolling out to veterinary market. 1 in every 4 dogs obtain cancer. Once efficacy (i.e. "golly it works!") is proven this is another near term revenue stream for the company. CEO later stated in the interview that he believes this revenue stream would begin within 9-12 month and that during the first full year this stream would bring in $6-10M. ($3,000 per treatment per canine.) This will also provide quite a bit of support for the human market (which is the ultimate goal).
-COPD 3rd leading cause of death in the U.S. Cures the problem and/or a return to some level of normalcy. They believe that FDA approval for their approach may come quicker than expected because the type of laser they use in the procedure are already approved and the medicine involved is also already approved. My understanding is that the FDA needs to approve the entire process...think of it as an entire orechestral arrangement rather than a violin solo!
-SHARE STRUCTURE (2.7M FLOAT WOW)
Approximately 17.5M issued and outstanding. 4 million freely tradeable
Of those 4 million there are only 2.7M shares in the DTC (real float)
"There's not alot of stock out there and we're not interested in flooding the market with stock. We're interested in our research and the direction of our company."
-Will you uplist to a higher exchange?
Currently ENTB is a fully reporting OTCBB company. But the CEO acknowledges that the greater the exchange the greater the visibility. And he thinks that higher visibility also helps with credibility which is vital in the biomedical field.
-Any larger stem cell companies taking an interest?
CEO believes there are alot of larger companies watching them and as they provide tangible results (gaining patents, preclinical and clinical trials, FDA approval, etc) there will be more intense interest.
-GRANTS. They have applied for $5-6M in grant funding this year alone. "It's not as good as revenue, but it's non-dilutive for shareholders!"
-Anyone that comes up with an actual treatment for COPD will dominate that market.
-COPD over the next 20 years is a $170B industry. Most of that money is being spent on drugs that provide short term relief only. If that money were spent toward a cure you would see a stabilization in money being spent on an annual basis. The company is working on a solution to the company not a way to perpetuate revenue for drug companies.
-Patents? They have somewhere around 10 patents filed that are pending.
"Our goal with Entest is not to be one of many companies doing the same thing. We believe that our niche that we have carved out in the COPD marketplace makes us unique. It also makes us one of the few companies out there to make a real differnece in an under-researched market. It has great social value. I can feel good about it. Shareholders can feel good about it. We're looking for positive solutions for social maladies." -- Dr. Koos
--------
All my posts are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on. For a complete disclaimerclick here
SAN DIEGO, CA--(Marketwire - 03/15/10) - Entest BioMedical Inc. (OTC.BB:ENTB - News) announced today It is creating a bioinformatics-based program combining advances in molecular knowledge of Chronic Obstructive Pulmonary Disease (COPD) with computer-powered search tools to integrate existing and newly generated data for this condition. Bioinformatics is defined as the collection, classification, storage, and analysis of biochemical and biological information using computers especially as applied in molecular genetics and genomics. One of the best known applications of bioinformatics methods is the Human Genome Project.
"While there are many pieces to the puzzle of COPD, the majority of research today is focused on finding new pieces as opposed to making sense of the pieces we already have," said Dr. Feng Lin, Scientific Director of Entest. "We have begun a Program based on using various automated algorithms to mine existing data sets and develop hypotheses that can be experimentally tested."
One of the initial tasks of the program is the creation of databases containing all genes associated with various aspects of COPD. These genes will then categorized based on biological functionality and association with each other. Once a global perspective of the genes and how their functions inter-relate is achieved, examination can be made as to which existing drugs may act somewhere on the pathway and possibility induce a benefit.
"By assembling everything known in the literature regarding COPD at a molecular level, our scientists will have an overall understanding of this terrible disease," said David Koos. "In addition, the bioinformatics approach will allow Entest to develop new intellectual property, some of which we anticipate will include new uses of existing drugs on the market."
The basis for the current program originates from internal Entest discussions involving the need for appropriate biomarkers for planned photoceutical trials. Given that the mechanism of action of photoceuticals is still relatively unclear, clinical trials will require sensitive biomarkers, which to some extent are not available in COPD. It is anticipated that the bioinformatics program will be of benefit in this aspect.
The Company will be hosting another interview with Its Chairman & CEO on Wednesday morning at 11 a.m. PDT at Live! | Entest BioMedical Blog - ENTB. Mr. Koos will discuss the importance of this new bioinformatics approach on strengthening Its COPD treatment model.
All my posts are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on. For a complete disclaimerclick here
LinkBack URL
About LinkBacks
Reply With Quote
Posting Permissions
FOLLOW US
in Social media